For citations:
Kazantsev I.V., Gevorgyan A.G., Yukhta T.V., Drozdovskaya D.A., Tolkunova P.S., Goncharova E.V., Kozlov A.V., Golenkova M.S., Galimov A.N., Bogdanova O.I., Punanov Yu.A., Kulagin A.D., Zubarovskaya L.S. Immunotherapy by anti-GD2 antibodies in patients with primary high-risk neuroblastoma, primary resistant and relapsed disease: Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg experience. Russian Journal of Pediatric Hematology and Oncology. 2021;8(3):14-29. (In Russ.) https://doi.org/10.21682/2311-1267-2021-8-3-14-29